Evidence map›Paper›PMID 32600329›Full record

ArticleMolecular cancer2020

Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation.

Mengyan Xie, Tao Yu, Xinming Jing, Ling Ma, Yu Fan, Fengming Yang, Pei Ma, Huning Jiang, Xi Wu, Yongqian Shu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 2 pooled it
27.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 2 syntheses or guidelines pooled it, 487 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mengyan XieDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tao YuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xinming JingDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ling MaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yu FanDepartment of Oncology, Zhenjiang First People's Hospital, Zhenjiang, China.
Fengming YangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pei MaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huning JiangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xi WuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yongqian ShuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. shuyongqian1998@163.com.ORCID 0000-0003-3122-7139
Tongpeng XuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Province Hospital · CNCentral People's Hospital of Zhanjiang · CNJiangsu Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) play important regulatory roles in the development of various cancers. However, biological functions and the underlying molecular mechanism of circRNAs in gastric cancer (GC) remain obscure.

methodsDifferentially expressed circRNAs were identified by RNA sequencing. The biological functions of circSHKBP1 in GC were investigated by a series of in vitro and in vivo experiments. The expression of circSHKBP1 was evaluated using quantitative real-time PCR and RNA in situ hybridization, and the molecular mechanism of circSHKBP1 was demonstrated by western blot, RNA pulldown, RNA immunoprecipitation, luciferase assays and rescue experiments. Lastly, mouse xenograft and bioluminescence imaging were used to exam the clinical relevance of circSHKBP1 in vivo.

resultsIncreased expression of circSHKBP1(hsa_circ_0000936) was revealed in GC tissues and serum and was related to advanced TNM stage and poor survival. The level of exosomal circSHKBP1 significantly decreased after gastrectomy. Overexpression of circSHKBP1 promoted GC cell proliferation, migration, invasion and angiogenesis in vitro and in vivo, while suppression of circSHKBP1 plays the opposite role. Exosomes with upregulated circSHKBP1 promoted cocultured cells growth. Mechanistically, circSHKBP1 sponged miR-582-3p to increase HUR expression, enhancing VEGF mRNA stability. Moreover, circSHKBP1 directly bound to HSP90 and obstructed the interaction of STUB1 with HSP90, inhibiting the ubiquitination of HSP90, resulting in accelerated GC development in vitro and in vivo.

conclusionOur findings demonstrate that exosomal circSHKBP1 regulates the miR-582-3p/HUR/VEGF pathway, suppresses HSP90 degradation, and promotes GC progression. circSHKBP1 is a promising circulating biomarker for GC diagnosis and prognosis and an exceptional candidate for further therapeutic exploration.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsApoptosisBiomarkers, TumorCase-Control StudiesCell ProliferationELAV-Like Protein 1ExosomesFemaleGene Expression Regulation, NeoplasticHSP90 Heat-Shock ProteinsHumansMaleMiceMice, Inbred BALB CMice, NudeAdaptor Proteins, Signal TransducingBiomarkers, TumorELAVL1 protein, humanELAV-Like Protein 1HSP90 Heat-Shock ProteinsMicroRNAsMIRN582 microRNA, humanRNA, CircularVascular Endothelial Growth Factor AVEGFA protein, humanCircSHKBP1ExosomeGastric cancerHSP90HURMiR-582-3pVEGF

Identifiers

PMID32600329
PMCPMC7322843
OpenAlexW3037315173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.